Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.76 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.72 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
| ▸ | SARS1 | P49591 | 1/20 | 0.71 |
| ▸ | NT5E | P21589 | 3/20 | 0.69 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.67 |
| ▸ | P2RY11 | Q96G91 | 4/20 | 0.67 |
| ▸ | IARS1 | P41252 | 1/20 | 0.67 |
| ▸ | MARS1 | P56192 | 1/20 | 0.65 |
| ▸ | CD99 | P14209 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29737838 | 1.00 | CA1 (1.00) | CA1CA2CA4CA9ADORA3 | |
| SCHEMBL2489469 | 1.00 | CA1 (1.00) | CA1CA2CA4CA9ADORA3 | |
| SCHEMBL14201599 | 1.00 | CA1 (1.00) | CA1CA2CA4CA9ADORA3 | |
| SCHEMBL18630526 | 0.90 | CA1 (0.81) | CA1CA2CA4CA9ADORA3 | |
| SCHEMBL14201600 | 0.88 | CA1 (0.78) | CA1CA2CA4CA9ADORA3 | |
| SCHEMBL10619733 | 0.88 | CA1 (0.78) | CA1CA2CA4CA9ADORA3 | |
| SCHEMBL4451649 | 0.86 | ADORA3 (1.00) | CA1CA2CA4CA9ADORA3 | |
| SCHEMBL4451640 | 0.86 | ADORA3 (1.00) | CA1CA2CA4CA9ADORA3 | |
| SCHEMBL5348320 | 0.86 | ADORA3 (1.00) | CA1CA2CA4CA9ADORA3 | |
| SCHEMBL5348325 | 0.86 | ADORA3 (1.00) | CA1CA2CA4CA9ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11228422-A | — | — | None | — | — | JP | disclosed |
| EP-1496056-B1 | NOVEL COMPOUNDS AND ANTIMALARIALS | UNIV OKAYAMA (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2074126-A2 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7407984-B2 | Tetraoxaspriro anti-malarials | OKAYAMA UNIVERSITY (JP) | 2008-08-05 | — | — | US | disclosed |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008049105-A2 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1262482-B1 | NOVEL TRIOXA TRICYCLIC COMPOUNDS HAVING ANTIMALARIAL ACTIVITY | JAPAN SCIENCE & TECH AGENCY (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-20050131058-A1 | Novel compounds and antimalarials | OKAYAMA UNIVERSITY (JP) | 2005-06-16 | — | — | US | disclosed |
| EP-1496056-A1 | NOVEL COMPOUNDS AND ANTIMALARIALS | Okayama University (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-6710074-B2 | FOR THERAPY OF MALARIA | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030078291-A1 | Novel compound having antimalarial activity | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1262482-A1 | NOVEL COMPOUND HAVING ANTIMALARIAL ACTIVITY | Japan Science and Technology Corporation (JP) | 2002-12-04 | — | — | EP | disclosed |
| JP-H11228422-A | ANTIMALARIAL AGENT | MITSUBISHI CHEMICAL CORP | 1999-08-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078291-A1 | Novel compound having antimalarial activity | CYP51A1, CASP12, TBXAS1 | CA1 3650/4885CA2 2212/4885CA4 3342/4885 |
| US-20050131058-A1 | Novel compounds and antimalarials | SQLE, NR1H3, ALOX15 | CA1 4704/4885CA2 4120/4885CA4 4725/4885 |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | CA1 4466/4885CA2 4557/4885CA4 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.